查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
2006246

支气管扩张治疗市场：2026-2032年全球市场预测（依药物类型、给药途径、病患族群、支气管扩张类型及分销管道划分）

Bronchiectasis Drugs Market by Drug Type, Route Of Administration, Patient Demographics, Bronchiectasis Type, Distribution Channel - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 186 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

2025 年支气管扩张治疗市场价值 16.5 亿美元，预计到 2026 年将成长至 18 亿美元，复合年增长率为 9.55%，到 2032 年将达到 31.3 亿美元。

主要市场统计数据
基准年 2025 16.5亿美元
预计年份：2026年 18亿美元
预测年份 2032 31.3亿美元
复合年增长率 (%) 9.55%

对支气管扩张药物治疗的进展、临床重点以及不断发展的治疗创新框架进行了简明扼要且权威的概述。

支气管扩张症已从临床实践中鲜少受到关注的疾病，转变为药物研发的重点，这得益于诊断准确性的提高、治疗假设的拓展以及对生活品质（QOL）日益重视。近年来，影像学、痰液微生物学和纵向患者登记技术的进步，促使研究方向趋于融合，涵盖抗发炎策略、标靶抗菌疗法、气道清除方法以及支气管扩张症的症状治疗。这种临床见解与转化科学的融合，使临床医生和相关人员不再将支气管扩张症视为一种不可避免的疾病进展，而是将其视为一种可治疗的慢性疾病。

深刻洞察标靶免疫调节、个人化治疗和给药方式的创新如何重塑支气管扩张的治疗模式。

支气管扩张的治疗格局正在经历一场变革性的转变，其驱动力包括靶向免疫调节、精准抗生素管理以及吸入系统的创新。首先，超越广泛使用糖皮质激素的抗发炎策略的出现——包括选择性通路调变器和佐剂——重塑了治疗模式，优先控制慢性炎症，同时避免不可接受的全身暴露。这一转变，加上对气道微生物组动态的更深入理解，正在推动旨在降低病原体负荷并维持微生物生态系统的抗生素和生物製药的研发。

对近期美国关税趋势如何推动呼吸系统治疗药物供应链的韧性、采购调整和筹资策略转变进行实际分析。

美国近期关税政策的变化为呼吸系统药物的跨境供应链和采购计画带来了新的不稳定性。儘管关税在不同产品类别和原材料类别中的适用程度不一，但它们会影响活性成分、辅料、成品和专用给药装置的采购决策。实际上，製造商和经销商正在重新审视供应商多元化、客户合约条款和接收成本模型，以维持供应的连续性和可预测的商业环境。

将治疗领域、给药途径、患者人口统计特征、疾病病理生理学和分销管道与策略决策联繫起来的综合细分框架。

精细的细分观点将药物特性、患者需求和通路相结合，从而明确支气管扩张症领域的治疗和商业策略。依药物类型分类，抗发炎药物（包括皮质类固醇和非类固醇消炎剂）主要针对慢性发炎环境，而抗生素则着重于抑制病原体和控制感染。支气管扩张剂分为长效和短效两种类型，以满足维持治疗和紧急治疗的需求，祛痰药则针对痰液黏稠度和排放机制。这种药理学分类有助于产品定位、处方集讨论和联合治疗决策。

从策略区域观点探讨医疗保健系统、法规结构和医疗保健服务生态系统如何影响全球市场支气管扩张治疗的取得和分配。

地理因素影响支气管扩张治疗的临床可近性、监管预期和商业化模式。在美洲，医疗保健系统呈现出一种混合模式，以医院主导监护和不断扩展的门诊服务为特色，并高度重视真实世界数据（REW）的生成以及与不同相关人员和支付方的互动。区域临床网路和病患登记系统支援长期疗效追踪和可操作性研究，这些研究构成了医保报销和指引制定的基础。

对支气管扩张治疗生态系中的主要企业进行详细的竞争定位、创新路径和合作模式分析。

支气管扩张治疗市场的竞争格局呈现出多元化的态势，既有经验丰富的呼吸专科医生，也有专注于生物技术的专业公司，还有大规模多元化製药企业。主要参与者通常透过专有的给药平台、生物製药或合理使用抗生素的策略来降低抗药性风险，从而实现差异化竞争。有些机构优先考虑渐进式创新，将已知的活性成分重新包装成吸入剂或长效製剂，以提高耐受性和患者依从性；而另一些机构则致力于First-in-Class的靶点，以调节参与粘液过度分泌和气道重塑的特定炎症通路。

针对支气管扩张症的治疗经营团队，提出切实有效的建议，旨在加速临床应用，增强韧性，并为患者带来可衡量的益处。

对于寻求持续差异化优势和提升患者疗效的行业领导者而言，一系列切实可行的方法可以加速临床应用和商业性成功。首先，应优先产生能够直接解决支付方和临床医生顾虑的证据：投资于临床试验和真实世界研究，以评估病情加重负担、功能性结局和医疗资源利用情况，并以可靠的患者报告结局来补充临床终点。其次，应优化给药方式以减轻治疗负担：吸入製剂和易于使用的製剂能够减少全身暴露，既符合临床医师的偏好，又能提高患者的依从性。

对混合方法研究途径进行透明的解释，该方法结合了临床证据审查、监管分析、相关人员访谈和产品生命週期评估。

本研究采用混合方法，结合了临床文献评估、监管环境审查、相关人员访谈以及医疗设备和製剂发展趋势分析。临床文献评估重点在于试验设计要素、终点选择以及各治疗类别的安全性概况。监管指南和已发布的申报文件经过仔细审查，以确定不断变化的核准标准和上市后证据要求。来自临床医生、药物负责人和供应链专家的关键定性意见被用于解读推广应用障碍和营运限制。

一项权威的综合分析强调了整合临床、营运和商业策略的必要性，以实现支气管扩张治疗的治疗价值。

维持支气管扩张治疗的良好势头需要一项整合策略，该策略应将科学创新、营运韧性和相关人员合作相结合。不断涌现的实证依证支持向临床差异化和用户友好型治疗方法转变，而商业性成功则取决于灵活的分销模式、引人入胜的支付方方案以及以患者为中心的疗效的显着改善。同样重要的是，要能够透过积极的规划和伙伴关係来应对供应链波动、监管差异和不断变化的临床预期。

目录

第一章：序言

第二章：调查方法

  • 调查设计
  • 研究框架
  • 市场规模预测
  • 数据三角测量
  • 调查结果
  • 调查的前提
  • 研究限制

第三章执行摘要

  • 首席主管观点
  • 市场规模和成长趋势
  • 2025年市占率分析
  • FPNV定位矩阵，2025
  • 新的商机
  • 下一代经营模式
  • 产业蓝图

第四章 市场概览

  • 产业生态系与价值链分析
  • 波特五力分析
  • PESTEL 分析
  • 市场展望
  • 市场进入策略

第五章 市场洞察

  • 消费者洞察与终端用户观点
  • 消费者体验基准
  • 机会映射
  • 分销通路分析
  • 价格趋势分析
  • 监理合规和标准框架
  • ESG与永续性分析
  • 中断和风险情景
  • 投资报酬率和成本效益分析

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

第八章：支气管扩张治疗药物市场（依药物类型划分）

  • 抗发炎药
    • 皮质类固醇
    • NSAIDs
  • 抗生素
  • 支气管扩张剂
    • 长效支气管扩张剂
    • 短效支气管扩张剂
  • 祛痰药

第九章：支气管扩张治疗市场：依给药途径划分

  • 吸入
  • 注射
    • 静脉
    • 皮下
  • 口服

第十章：依患者细分分類的支气管扩张治疗市场

  • 成人版
  • 老年人
  • 儿童

第十一章：以支气管扩张类型分類的支气管扩张治疗市场

  • 圆柱形（管状）
  • 类似静脉曲张的（囊性）

第十二章 支气管扩张治疗市场：依通路划分

  • 医院药房
  • 网路药房
  • 零售药房

第十三章 支气管扩张治疗市场：依地区划分

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十四章 支气管扩张治疗市场：依组别划分

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十五章 支气管扩张治疗市场：依国家划分

  • 我们
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十六章：美国支气管扩张治疗市场

第十七章：中国支气管扩张治疗市场

第十八章 竞争格局

  • 市场集中度分析，2025年
    • 浓度比（CR）
    • 赫芬达尔-赫希曼指数 (HHI)
  • 近期趋势及影响分析，2025 年
  • 2025年产品系列分析
  • 基准分析，2025 年
  • AdvaCare Pharma
  • Armata Pharmaceuticals
  • AstraZeneca PLC
  • Bayer AG
  • Boehringer Ingelheim International GmbH
  • Cipla Limited
  • F. Hoffmann-La Roche AG
  • GlaxoSmithKline PLC
  • Glenmark Pharmaceuticals Limited
  • Insmed Incorporated
  • Lupin Limited
  • Merck & Co., Inc.
  • Mylan Inc. by Viatris Inc.
  • Nephron Pharmaceuticals Corporation
  • Novartis AG
  • Perrigo Company PLC
  • Pfizer Inc.
  • Renovion, Inc.
  • Sanofi SA
  • Steris Healthcare Pvt. Ltd.
  • Sun Pharmaceutical Industries Limited
  • Teva Pharmaceutical Industries Ltd.
  • Verona Pharma PLC
  • ZAMBON COMPANY SPA
  • Zydus Group
Product Code: MRR-B1685377A3D9

The Bronchiectasis Drugs Market was valued at USD 1.65 billion in 2025 and is projected to grow to USD 1.80 billion in 2026, with a CAGR of 9.55%, reaching USD 3.13 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 1.65 billion
Estimated Year [2026] USD 1.80 billion
Forecast Year [2032] USD 3.13 billion
CAGR (%) 9.55%

A concise and authoritative orientation to bronchiectasis pharmacotherapy developments, clinical priorities, and the evolving framework for therapeutic innovation

Bronchiectasis has emerged from clinical obscurity to become a focal point for drug development, driven by improved diagnostic recognition, expanding therapeutic hypotheses, and a growing emphasis on quality-of-life outcomes. Recent years have seen a convergence of research efforts across anti-inflammatory strategies, targeted antimicrobial approaches, airway clearance modalities, and symptomatic bronchodilation, all informed by advances in imaging, sputum microbiology, and longitudinal patient registries. This combination of clinical insight and translational science has reshaped how clinicians and industry stakeholders view the disease as a treatable chronic condition rather than an inevitably progressive one.

Consequently, pipelines now reflect a blend of repurposed agents, novel molecular entities, and delivery-optimized formulations intended to address the multifactorial pathophysiology of bronchiectasis. Regulatory dialogues increasingly emphasize patient-reported outcomes and exacerbation reduction as meaningful endpoints, while payers and providers focus on therapies that demonstrably reduce healthcare utilization and improve daily functioning. As a result, strategic decision-making requires an integrated view of clinical evidence, therapeutic differentiation, and practical adoption barriers to translate scientific advances into sustainable patient benefit.

An incisive account of how targeted immunomodulation, therapeutic personalization, and delivery innovation are reshaping treatment paradigms for bronchiectasis

The therapeutic landscape for bronchiectasis is undergoing transformative shifts driven by targeted immunomodulation, precision antimicrobial stewardship, and innovations in inhalation delivery systems. First, the emergence of anti-inflammatory strategies that extend beyond broad corticosteroid use-incorporating selective pathway modulators and adjunctive agents-has reframed treatment paradigms to prioritize chronic inflammation control without unacceptable systemic exposure. This shift is coupled with a more nuanced appreciation of airway microbiome dynamics, prompting development of antibiotics and biologics that aim to reduce pathogenic burden while preserving microbial ecology.

Concurrently, device- and formulation-driven advances have reduced the friction of long-term therapy, with inhaled formulations and optimized nebulizer technologies enabling higher local drug concentrations and improved tolerability. On the regulatory and evidence front, stakeholders now place greater weight on patient-centered endpoints, including exacerbation frequency, functional capacity, and health-related quality of life, which in turn influences trial design and postmarketing value demonstration. Taken together, these shifts are fostering a more patient-centric, precision-oriented approach to bronchiectasis management that aligns clinical objectives with product innovation and adoption pathways.

A pragmatic exploration of how recent United States tariff dynamics are prompting supply chain resilience, sourcing adjustments, and procurement strategy shifts in respiratory therapeutics

Recent tariff developments in the United States have introduced a new variable into cross-border supply chains and procurement planning for respiratory pharmaceuticals. While tariffs are applied unevenly across product classes and raw material categories, they can influence sourcing decisions for active pharmaceutical ingredients, excipients, finished dosage forms, and specialized delivery devices. In practice, manufacturers and distributors are reassessing supplier diversification, client contractual terms, and landed-cost models to maintain supply continuity and predictable commercial terms.

In response to tariff-induced cost pressure, several industry participants have either accelerated localization of manufacturing capacity, negotiated longer-term supply contracts with hedging provisions, or optimized product portfolios to prioritize formulations and packaging formats that are less exposed to incremental duties. Buyers and health systems, in turn, are revisiting tender structures and inventory strategies to mitigate short-term price volatility. Crucially, these operational adjustments emphasize resilience: supply chain visibility, alternative sourcing, and collaborative planning with logistics partners help ensure that patient access and therapeutic continuity remain intact despite tariff-related headwinds.

A comprehensive segmentation framework linking therapeutic class, administration route, patient cohorts, disease morphology, and distribution channels to strategic decision-making

A refined segmentation lens clarifies therapeutic and commercial strategies across the bronchiectasis landscape by aligning drug attributes, patient needs, and distribution pathways. When classifying by drug type, anti-inflammatory agents-including corticosteroids and nonsteroidal anti-inflammatory agents-address the chronic inflammatory milieu, while antibiotics concentrate on pathogen suppression and infection control; bronchodilators are differentiated into long-acting and short-acting agents to meet both maintenance and rescue needs, and mucolytics target sputum viscosity and clearance mechanics. This pharmacologic taxonomy informs product positioning, formulary discussions, and combination regimens.

Route of administration drives adherence and delivery considerations: inhalation approaches minimize systemic exposure and support home-based therapy, injection routes-comprising both intravenous and subcutaneous options-are reserved for severe exacerbations or biologic therapies, and oral therapies remain central for ease of use and outpatient management. Patient demographics further nuance clinical strategy, as adult, geriatric, and pediatric populations present differing comorbidity profiles, tolerability windows, and dosing requirements. Disease subtype stratification between cylindrical (tubular) and varicose (cystic) bronchiectasis contributes diagnostic and prognostic context that can influence therapeutic choice and trial cohort selection. Finally, distribution channel segmentation across hospital pharmacies, online pharmacies, and retail pharmacies defines access touchpoints, reimbursement workflows, and patient support program design, all of which are essential for achieving meaningful uptake and sustained adherence.

A strategic regional perspective on how healthcare systems, regulatory frameworks, and delivery ecosystems shape bronchiectasis therapy access and adoption across global markets

Geographic contours shape clinical access, regulatory expectations, and commercialization approaches for bronchiectasis therapies. In the Americas, healthcare systems demonstrate a mix of centralized hospital-led care and expanding outpatient services, with strong emphasis on real-world evidence generation and multi-stakeholder payer engagements. Clinical networks and patient registries in this region support longitudinal outcome tracking and pragmatic studies that inform reimbursement dossiers and guideline development.

Across Europe, Middle East & Africa, regulatory harmonization efforts and diverse reimbursement environments necessitate adaptable clinical narratives and localized health economic arguments. In several jurisdictions, accelerated pathways for unmet-need respiratory therapies coexist with rigorous cost-effectiveness evaluation, requiring tailored evidence packages. In the Asia-Pacific region, heterogeneity in healthcare infrastructure, rapid adoption of inhalation technologies, and growing investment in local manufacturing capacity drive distinct commercialization strategies; partnerships with regional distributors and attention to cold-chain and logistics considerations can materially affect availability and uptake. Taken together, these regional differences underline the importance of flexible market entry plans and evidence generation strategies that reflect local payer priorities and clinical practice patterns.

An informed analysis of competitive positioning, innovation pathways, and collaborative models that define leading companies in the bronchiectasis therapeutics ecosystem

Competitive dynamics in bronchiectasis therapeutics reflect a mix of established respiratory specialists, specialty biotech firms, and larger diversified pharmaceutical companies. Key players often differentiate through proprietary delivery platforms, biologic modalities, or antimicrobial stewardship strategies that reduce resistance risk. Some organizations prioritize incremental innovation by reformulating known active molecules into inhaled or longer-acting forms, thereby improving tolerability and adherence, while others pursue first-in-class targets that modulate specific inflammatory pathways implicated in mucus hypersecretion and airway remodeling.

Collaboration is increasingly prominent, as clinical development often requires access to specialized registries, diagnostic capabilities, and patient support services. Partnerships between developers and contract manufacturing organizations enable flexible scale-up and localized production, and licensing agreements are used to accelerate geographic expansion. From a commercial perspective, market entrants that combine strong clinical differentiation with robust patient support and healthcare professional education programs are better positioned to secure formulary placement and clinical adoption. Moreover, organizations that invest in post-authorization evidence generation and digital adherence solutions tend to strengthen their long-term value propositions.

Practical, high-impact recommendations for leadership teams to accelerate clinical adoption, enhance resilience, and deliver measurable patient benefit in bronchiectasis care

For industry leaders seeking durable differentiation and patient impact, a set of pragmatic actions can accelerate clinical adoption and commercial success. First, prioritize evidence generation that directly addresses payer and clinician concerns: invest in trials and real-world studies that measure exacerbation burden, functional outcomes, and healthcare resource utilization, and complement clinical endpoints with robust patient-reported measures. Second, optimize delivery modalities to lower treatment burden; inhaled and user-friendly formulations that reduce systemic exposure will align with both clinician preference and patient adherence.

Next, strengthen supply chain resilience through supplier diversification, regional manufacturing partnerships, and inventory strategies that reduce vulnerability to tariff and logistics disruptions. Additionally, design distribution and patient support pathways that integrate hospital, retail, and digital pharmacy channels to maximize accessibility and continuity of care. Finally, invest in cross-functional stakeholder engagement-clinical champions, payer evidence teams, and patient advocacy groups-to create aligned value narratives that expedite inclusion in treatment protocols and formularies. These coordinated steps enhance the likelihood that therapeutic innovations translate into improved outcomes and sustained clinical uptake.

A transparent explanation of the mixed-methods research approach blending clinical evidence review, regulatory analysis, stakeholder interviews, and product lifecycle assessment

This research synthesis is grounded in a mixed-methods approach that combines clinical literature appraisal, regulatory landscape review, stakeholder interviews, and synthesis of device and formulation trends. Clinical literature was evaluated with attention to trial design elements, endpoint selection, and safety profiles across therapeutic classes. Regulatory guidance and public filings were examined to identify evolving approval criteria and postmarketing evidence expectations. Primary qualitative inputs from clinicians, formulary managers, and supply chain specialists informed interpretation of adoption barriers and operational constraints.

Complementing qualitative inputs, product and technology assessments focused on delivery systems, manufacturing dependencies, and cold-chain or handling requirements. Cross-validation techniques were used to reconcile disparate data points and ensure consistency of conclusions. Where applicable, sensitivity to regional regulatory and reimbursement variance was applied to refine strategic implications. This blended methodology provides a robust foundation for the insights and recommendations presented, emphasizing practical applicability for clinical development, commercialization, and operations teams.

A conclusive synthesis underscoring the need for integrated clinical, operational, and commercial strategies to realize therapeutic value in bronchiectasis care

Sustaining momentum in bronchiectasis therapeutics requires integrated strategies that bridge scientific innovation, operational resilience, and stakeholder alignment. The evolving evidence base supports a transition toward therapies that are both clinically differentiated and user-friendly, while commercial success will hinge on adaptable distribution models, compelling payer narratives, and demonstrable improvements in patient-centered outcomes. Equally important is the ability to navigate supply chain volatility, regulatory diversity, and shifting clinical expectations with proactive planning and partnership.

Ultimately, the most effective programs will align therapeutic design with real-world use, coupling clinical efficacy with mechanisms to support adherence, access, and long-term value demonstration. Organizations that embrace this holistic view-investing in targeted evidence, resilient operations, and sustained stakeholder engagement-will be best positioned to convert scientific advances into meaningful improvement in patient care and health system performance.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Bronchiectasis Drugs Market, by Drug Type

  • 8.1. Anti-Inflammatory Agents
    • 8.1.1. Corticosteroids
    • 8.1.2. NSAIDs
  • 8.2. Antibiotics
  • 8.3. Bronchodilators
    • 8.3.1. Long-Acting Bronchodilators
    • 8.3.2. Short-Acting Bronchodilators
  • 8.4. Mucolytics

9. Bronchiectasis Drugs Market, by Route Of Administration

  • 9.1. Inhalation
  • 9.2. Injection
    • 9.2.1. Intravenous
    • 9.2.2. Subcutaneous
  • 9.3. Oral

10. Bronchiectasis Drugs Market, by Patient Demographics

  • 10.1. Adult
  • 10.2. Geriatric
  • 10.3. Pediatric

11. Bronchiectasis Drugs Market, by Bronchiectasis Type

  • 11.1. Cylindrical (Tubular)
  • 11.2. Varicose (Cystic)

12. Bronchiectasis Drugs Market, by Distribution Channel

  • 12.1. Hospital Pharmacies
  • 12.2. Online Pharmacies
  • 12.3. Retail Pharmacies

13. Bronchiectasis Drugs Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Bronchiectasis Drugs Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Bronchiectasis Drugs Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. United States Bronchiectasis Drugs Market

17. China Bronchiectasis Drugs Market

18. Competitive Landscape

  • 18.1. Market Concentration Analysis, 2025
    • 18.1.1. Concentration Ratio (CR)
    • 18.1.2. Herfindahl Hirschman Index (HHI)
  • 18.2. Recent Developments & Impact Analysis, 2025
  • 18.3. Product Portfolio Analysis, 2025
  • 18.4. Benchmarking Analysis, 2025
  • 18.5. AdvaCare Pharma
  • 18.6. Armata Pharmaceuticals
  • 18.7. AstraZeneca PLC
  • 18.8. Bayer AG
  • 18.9. Boehringer Ingelheim International GmbH
  • 18.10. Cipla Limited
  • 18.11. F. Hoffmann-La Roche AG
  • 18.12. GlaxoSmithKline PLC
  • 18.13. Glenmark Pharmaceuticals Limited
  • 18.14. Insmed Incorporated
  • 18.15. Lupin Limited
  • 18.16. Merck & Co., Inc.
  • 18.17. Mylan Inc. by Viatris Inc.
  • 18.18. Nephron Pharmaceuticals Corporation
  • 18.19. Novartis AG
  • 18.20. Perrigo Company PLC
  • 18.21. Pfizer Inc.
  • 18.22. Renovion, Inc.
  • 18.23. Sanofi S.A.
  • 18.24. Steris Healthcare Pvt. Ltd.
  • 18.25. Sun Pharmaceutical Industries Limited
  • 18.26. Teva Pharmaceutical Industries Ltd.
  • 18.27. Verona Pharma PLC
  • 18.28. ZAMBON COMPANY S.P.A.
  • 18.29. Zydus Group

LIST OF FIGURES

  • FIGURE 1. GLOBAL BRONCHIECTASIS DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL BRONCHIECTASIS DRUGS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL BRONCHIECTASIS DRUGS MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL BRONCHIECTASIS DRUGS MARKET SIZE, BY DRUG TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL BRONCHIECTASIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL BRONCHIECTASIS DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL BRONCHIECTASIS DRUGS MARKET SIZE, BY BRONCHIECTASIS TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL BRONCHIECTASIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL BRONCHIECTASIS DRUGS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL BRONCHIECTASIS DRUGS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL BRONCHIECTASIS DRUGS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. UNITED STATES BRONCHIECTASIS DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 13. CHINA BRONCHIECTASIS DRUGS MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL BRONCHIECTASIS DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL BRONCHIECTASIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL BRONCHIECTASIS DRUGS MARKET SIZE, BY ANTI-INFLAMMATORY AGENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL BRONCHIECTASIS DRUGS MARKET SIZE, BY ANTI-INFLAMMATORY AGENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL BRONCHIECTASIS DRUGS MARKET SIZE, BY ANTI-INFLAMMATORY AGENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL BRONCHIECTASIS DRUGS MARKET SIZE, BY ANTI-INFLAMMATORY AGENTS, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL BRONCHIECTASIS DRUGS MARKET SIZE, BY CORTICOSTEROIDS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL BRONCHIECTASIS DRUGS MARKET SIZE, BY CORTICOSTEROIDS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL BRONCHIECTASIS DRUGS MARKET SIZE, BY CORTICOSTEROIDS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL BRONCHIECTASIS DRUGS MARKET SIZE, BY NSAIDS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL BRONCHIECTASIS DRUGS MARKET SIZE, BY NSAIDS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL BRONCHIECTASIS DRUGS MARKET SIZE, BY NSAIDS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL BRONCHIECTASIS DRUGS MARKET SIZE, BY ANTIBIOTICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL BRONCHIECTASIS DRUGS MARKET SIZE, BY ANTIBIOTICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL BRONCHIECTASIS DRUGS MARKET SIZE, BY ANTIBIOTICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL BRONCHIECTASIS DRUGS MARKET SIZE, BY BRONCHODILATORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL BRONCHIECTASIS DRUGS MARKET SIZE, BY BRONCHODILATORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL BRONCHIECTASIS DRUGS MARKET SIZE, BY BRONCHODILATORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL BRONCHIECTASIS DRUGS MARKET SIZE, BY BRONCHODILATORS, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL BRONCHIECTASIS DRUGS MARKET SIZE, BY LONG-ACTING BRONCHODILATORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL BRONCHIECTASIS DRUGS MARKET SIZE, BY LONG-ACTING BRONCHODILATORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL BRONCHIECTASIS DRUGS MARKET SIZE, BY LONG-ACTING BRONCHODILATORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL BRONCHIECTASIS DRUGS MARKET SIZE, BY SHORT-ACTING BRONCHODILATORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL BRONCHIECTASIS DRUGS MARKET SIZE, BY SHORT-ACTING BRONCHODILATORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL BRONCHIECTASIS DRUGS MARKET SIZE, BY SHORT-ACTING BRONCHODILATORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL BRONCHIECTASIS DRUGS MARKET SIZE, BY MUCOLYTICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL BRONCHIECTASIS DRUGS MARKET SIZE, BY MUCOLYTICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL BRONCHIECTASIS DRUGS MARKET SIZE, BY MUCOLYTICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL BRONCHIECTASIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL BRONCHIECTASIS DRUGS MARKET SIZE, BY INHALATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL BRONCHIECTASIS DRUGS MARKET SIZE, BY INHALATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL BRONCHIECTASIS DRUGS MARKET SIZE, BY INHALATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL BRONCHIECTASIS DRUGS MARKET SIZE, BY INJECTION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL BRONCHIECTASIS DRUGS MARKET SIZE, BY INJECTION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL BRONCHIECTASIS DRUGS MARKET SIZE, BY INJECTION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL BRONCHIECTASIS DRUGS MARKET SIZE, BY INJECTION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL BRONCHIECTASIS DRUGS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL BRONCHIECTASIS DRUGS MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL BRONCHIECTASIS DRUGS MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL BRONCHIECTASIS DRUGS MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL BRONCHIECTASIS DRUGS MARKET SIZE, BY SUBCUTANEOUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL BRONCHIECTASIS DRUGS MARKET SIZE, BY SUBCUTANEOUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL BRONCHIECTASIS DRUGS MARKET SIZE, BY ORAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL BRONCHIECTASIS DRUGS MARKET SIZE, BY ORAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL BRONCHIECTASIS DRUGS MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL BRONCHIECTASIS DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL BRONCHIECTASIS DRUGS MARKET SIZE, BY ADULT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL BRONCHIECTASIS DRUGS MARKET SIZE, BY ADULT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL BRONCHIECTASIS DRUGS MARKET SIZE, BY ADULT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL BRONCHIECTASIS DRUGS MARKET SIZE, BY GERIATRIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL BRONCHIECTASIS DRUGS MARKET SIZE, BY GERIATRIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL BRONCHIECTASIS DRUGS MARKET SIZE, BY GERIATRIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL BRONCHIECTASIS DRUGS MARKET SIZE, BY PEDIATRIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL BRONCHIECTASIS DRUGS MARKET SIZE, BY PEDIATRIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL BRONCHIECTASIS DRUGS MARKET SIZE, BY PEDIATRIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL BRONCHIECTASIS DRUGS MARKET SIZE, BY BRONCHIECTASIS TYPE, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL BRONCHIECTASIS DRUGS MARKET SIZE, BY CYLINDRICAL (TUBULAR), BY REGION, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL BRONCHIECTASIS DRUGS MARKET SIZE, BY CYLINDRICAL (TUBULAR), BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL BRONCHIECTASIS DRUGS MARKET SIZE, BY CYLINDRICAL (TUBULAR), BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL BRONCHIECTASIS DRUGS MARKET SIZE, BY VARICOSE (CYSTIC), BY REGION, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL BRONCHIECTASIS DRUGS MARKET SIZE, BY VARICOSE (CYSTIC), BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL BRONCHIECTASIS DRUGS MARKET SIZE, BY VARICOSE (CYSTIC), BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL BRONCHIECTASIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL BRONCHIECTASIS DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL BRONCHIECTASIS DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL BRONCHIECTASIS DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL BRONCHIECTASIS DRUGS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL BRONCHIECTASIS DRUGS MARKET SIZE, BY ONLINE PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL BRONCHIECTASIS DRUGS MARKET SIZE, BY ONLINE PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL BRONCHIECTASIS DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL BRONCHIECTASIS DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL BRONCHIECTASIS DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL BRONCHIECTASIS DRUGS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 74. AMERICAS BRONCHIECTASIS DRUGS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 75. AMERICAS BRONCHIECTASIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 76. AMERICAS BRONCHIECTASIS DRUGS MARKET SIZE, BY ANTI-INFLAMMATORY AGENTS, 2018-2032 (USD MILLION)
  • TABLE 77. AMERICAS BRONCHIECTASIS DRUGS MARKET SIZE, BY BRONCHODILATORS, 2018-2032 (USD MILLION)
  • TABLE 78. AMERICAS BRONCHIECTASIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 79. AMERICAS BRONCHIECTASIS DRUGS MARKET SIZE, BY INJECTION, 2018-2032 (USD MILLION)
  • TABLE 80. AMERICAS BRONCHIECTASIS DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD MILLION)
  • TABLE 81. AMERICAS BRONCHIECTASIS DRUGS MARKET SIZE, BY BRONCHIECTASIS TYPE, 2018-2032 (USD MILLION)
  • TABLE 82. AMERICAS BRONCHIECTASIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 83. NORTH AMERICA BRONCHIECTASIS DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 84. NORTH AMERICA BRONCHIECTASIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 85. NORTH AMERICA BRONCHIECTASIS DRUGS MARKET SIZE, BY ANTI-INFLAMMATORY AGENTS, 2018-2032 (USD MILLION)
  • TABLE 86. NORTH AMERICA BRONCHIECTASIS DRUGS MARKET SIZE, BY BRONCHODILATORS, 2018-2032 (USD MILLION)
  • TABLE 87. NORTH AMERICA BRONCHIECTASIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 88. NORTH AMERICA BRONCHIECTASIS DRUGS MARKET SIZE, BY INJECTION, 2018-2032 (USD MILLION)
  • TABLE 89. NORTH AMERICA BRONCHIECTASIS DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD MILLION)
  • TABLE 90. NORTH AMERICA BRONCHIECTASIS DRUGS MARKET SIZE, BY BRONCHIECTASIS TYPE, 2018-2032 (USD MILLION)
  • TABLE 91. NORTH AMERICA BRONCHIECTASIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 92. LATIN AMERICA BRONCHIECTASIS DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 93. LATIN AMERICA BRONCHIECTASIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 94. LATIN AMERICA BRONCHIECTASIS DRUGS MARKET SIZE, BY ANTI-INFLAMMATORY AGENTS, 2018-2032 (USD MILLION)
  • TABLE 95. LATIN AMERICA BRONCHIECTASIS DRUGS MARKET SIZE, BY BRONCHODILATORS, 2018-2032 (USD MILLION)
  • TABLE 96. LATIN AMERICA BRONCHIECTASIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 97. LATIN AMERICA BRONCHIECTASIS DRUGS MARKET SIZE, BY INJECTION, 2018-2032 (USD MILLION)
  • TABLE 98. LATIN AMERICA BRONCHIECTASIS DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD MILLION)
  • TABLE 99. LATIN AMERICA BRONCHIECTASIS DRUGS MARKET SIZE, BY BRONCHIECTASIS TYPE, 2018-2032 (USD MILLION)
  • TABLE 100. LATIN AMERICA BRONCHIECTASIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 101. EUROPE, MIDDLE EAST & AFRICA BRONCHIECTASIS DRUGS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 102. EUROPE, MIDDLE EAST & AFRICA BRONCHIECTASIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 103. EUROPE, MIDDLE EAST & AFRICA BRONCHIECTASIS DRUGS MARKET SIZE, BY ANTI-INFLAMMATORY AGENTS, 2018-2032 (USD MILLION)
  • TABLE 104. EUROPE, MIDDLE EAST & AFRICA BRONCHIECTASIS DRUGS MARKET SIZE, BY BRONCHODILATORS, 2018-2032 (USD MILLION)
  • TABLE 105. EUROPE, MIDDLE EAST & AFRICA BRONCHIECTASIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 106. EUROPE, MIDDLE EAST & AFRICA BRONCHIECTASIS DRUGS MARKET SIZE, BY INJECTION, 2018-2032 (USD MILLION)
  • TABLE 107. EUROPE, MIDDLE EAST & AFRICA BRONCHIECTASIS DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD MILLION)
  • TABLE 108. EUROPE, MIDDLE EAST & AFRICA BRONCHIECTASIS DRUGS MARKET SIZE, BY BRONCHIECTASIS TYPE, 2018-2032 (USD MILLION)
  • TABLE 109. EUROPE, MIDDLE EAST & AFRICA BRONCHIECTASIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 110. EUROPE BRONCHIECTASIS DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 111. EUROPE BRONCHIECTASIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 112. EUROPE BRONCHIECTASIS DRUGS MARKET SIZE, BY ANTI-INFLAMMATORY AGENTS, 2018-2032 (USD MILLION)
  • TABLE 113. EUROPE BRONCHIECTASIS DRUGS MARKET SIZE, BY BRONCHODILATORS, 2018-2032 (USD MILLION)
  • TABLE 114. EUROPE BRONCHIECTASIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 115. EUROPE BRONCHIECTASIS DRUGS MARKET SIZE, BY INJECTION, 2018-2032 (USD MILLION)
  • TABLE 116. EUROPE BRONCHIECTASIS DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD MILLION)
  • TABLE 117. EUROPE BRONCHIECTASIS DRUGS MARKET SIZE, BY BRONCHIECTASIS TYPE, 2018-2032 (USD MILLION)
  • TABLE 118. EUROPE BRONCHIECTASIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 119. MIDDLE EAST BRONCHIECTASIS DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 120. MIDDLE EAST BRONCHIECTASIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 121. MIDDLE EAST BRONCHIECTASIS DRUGS MARKET SIZE, BY ANTI-INFLAMMATORY AGENTS, 2018-2032 (USD MILLION)
  • TABLE 122. MIDDLE EAST BRONCHIECTASIS DRUGS MARKET SIZE, BY BRONCHODILATORS, 2018-2032 (USD MILLION)
  • TABLE 123. MIDDLE EAST BRONCHIECTASIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 124. MIDDLE EAST BRONCHIECTASIS DRUGS MARKET SIZE, BY INJECTION, 2018-2032 (USD MILLION)
  • TABLE 125. MIDDLE EAST BRONCHIECTASIS DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD MILLION)
  • TABLE 126. MIDDLE EAST BRONCHIECTASIS DRUGS MARKET SIZE, BY BRONCHIECTASIS TYPE, 2018-2032 (USD MILLION)
  • TABLE 127. MIDDLE EAST BRONCHIECTASIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 128. AFRICA BRONCHIECTASIS DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 129. AFRICA BRONCHIECTASIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 130. AFRICA BRONCHIECTASIS DRUGS MARKET SIZE, BY ANTI-INFLAMMATORY AGENTS, 2018-2032 (USD MILLION)
  • TABLE 131. AFRICA BRONCHIECTASIS DRUGS MARKET SIZE, BY BRONCHODILATORS, 2018-2032 (USD MILLION)
  • TABLE 132. AFRICA BRONCHIECTASIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 133. AFRICA BRONCHIECTASIS DRUGS MARKET SIZE, BY INJECTION, 2018-2032 (USD MILLION)
  • TABLE 134. AFRICA BRONCHIECTASIS DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD MILLION)
  • TABLE 135. AFRICA BRONCHIECTASIS DRUGS MARKET SIZE, BY BRONCHIECTASIS TYPE, 2018-2032 (USD MILLION)
  • TABLE 136. AFRICA BRONCHIECTASIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 137. ASIA-PACIFIC BRONCHIECTASIS DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 138. ASIA-PACIFIC BRONCHIECTASIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 139. ASIA-PACIFIC BRONCHIECTASIS DRUGS MARKET SIZE, BY ANTI-INFLAMMATORY AGENTS, 2018-2032 (USD MILLION)
  • TABLE 140. ASIA-PACIFIC BRONCHIECTASIS DRUGS MARKET SIZE, BY BRONCHODILATORS, 2018-2032 (USD MILLION)
  • TABLE 141. ASIA-PACIFIC BRONCHIECTASIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 142. ASIA-PACIFIC BRONCHIECTASIS DRUGS MARKET SIZE, BY INJECTION, 2018-2032 (USD MILLION)
  • TABLE 143. ASIA-PACIFIC BRONCHIECTASIS DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD MILLION)
  • TABLE 144. ASIA-PACIFIC BRONCHIECTASIS DRUGS MARKET SIZE, BY BRONCHIECTASIS TYPE, 2018-2032 (USD MILLION)
  • TABLE 145. ASIA-PACIFIC BRONCHIECTASIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 146. GLOBAL BRONCHIECTASIS DRUGS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 147. ASEAN BRONCHIECTASIS DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 148. ASEAN BRONCHIECTASIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 149. ASEAN BRONCHIECTASIS DRUGS MARKET SIZE, BY ANTI-INFLAMMATORY AGENTS, 2018-2032 (USD MILLION)
  • TABLE 150. ASEAN BRONCHIECTASIS DRUGS MARKET SIZE, BY BRONCHODILATORS, 2018-2032 (USD MILLION)
  • TABLE 151. ASEAN BRONCHIECTASIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 152. ASEAN BRONCHIECTASIS DRUGS MARKET SIZE, BY INJECTION, 2018-2032 (USD MILLION)
  • TABLE 153. ASEAN BRONCHIECTASIS DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD MILLION)
  • TABLE 154. ASEAN BRONCHIECTASIS DRUGS MARKET SIZE, BY BRONCHIECTASIS TYPE, 2018-2032 (USD MILLION)
  • TABLE 155. ASEAN BRONCHIECTASIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 156. GCC BRONCHIECTASIS DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 157. GCC BRONCHIECTASIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 158. GCC BRONCHIECTASIS DRUGS MARKET SIZE, BY ANTI-INFLAMMATORY AGENTS, 2018-2032 (USD MILLION)
  • TABLE 159. GCC BRONCHIECTASIS DRUGS MARKET SIZE, BY BRONCHODILATORS, 2018-2032 (USD MILLION)
  • TABLE 160. GCC BRONCHIECTASIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 161. GCC BRONCHIECTASIS DRUGS MARKET SIZE, BY INJECTION, 2018-2032 (USD MILLION)
  • TABLE 162. GCC BRONCHIECTASIS DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD MILLION)
  • TABLE 163. GCC BRONCHIECTASIS DRUGS MARKET SIZE, BY BRONCHIECTASIS TYPE, 2018-2032 (USD MILLION)
  • TABLE 164. GCC BRONCHIECTASIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 165. EUROPEAN UNION BRONCHIECTASIS DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 166. EUROPEAN UNION BRONCHIECTASIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 167. EUROPEAN UNION BRONCHIECTASIS DRUGS MARKET SIZE, BY ANTI-INFLAMMATORY AGENTS, 2018-2032 (USD MILLION)
  • TABLE 168. EUROPEAN UNION BRONCHIECTASIS DRUGS MARKET SIZE, BY BRONCHODILATORS, 2018-2032 (USD MILLION)
  • TABLE 169. EUROPEAN UNION BRONCHIECTASIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 170. EUROPEAN UNION BRONCHIECTASIS DRUGS MARKET SIZE, BY INJECTION, 2018-2032 (USD MILLION)
  • TABLE 171. EUROPEAN UNION BRONCHIECTASIS DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD MILLION)
  • TABLE 172. EUROPEAN UNION BRONCHIECTASIS DRUGS MARKET SIZE, BY BRONCHIECTASIS TYPE, 2018-2032 (USD MILLION)
  • TABLE 173. EUROPEAN UNION BRONCHIECTASIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 174. BRICS BRONCHIECTASIS DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 175. BRICS BRONCHIECTASIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 176. BRICS BRONCHIECTASIS DRUGS MARKET SIZE, BY ANTI-INFLAMMATORY AGENTS, 2018-2032 (USD MILLION)
  • TABLE 177. BRICS BRONCHIECTASIS DRUGS MARKET SIZE, BY BRONCHODILATORS, 2018-2032 (USD MILLION)
  • TABLE 178. BRICS BRONCHIECTASIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 179. BRICS BRONCHIECTASIS DRUGS MARKET SIZE, BY INJECTION, 2018-2032 (USD MILLION)
  • TABLE 180. BRICS BRONCHIECTASIS DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD MILLION)
  • TABLE 181. BRICS BRONCHIECTASIS DRUGS MARKET SIZE, BY BRONCHIECTASIS TYPE, 2018-2032 (USD MILLION)
  • TABLE 182. BRICS BRONCHIECTASIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 183. G7 BRONCHIECTASIS DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 184. G7 BRONCHIECTASIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 185. G7 BRONCHIECTASIS DRUGS MARKET SIZE, BY ANTI-INFLAMMATORY AGENTS, 2018-2032 (USD MILLION)
  • TABLE 186. G7 BRONCHIECTASIS DRUGS MARKET SIZE, BY BRONCHODILATORS, 2018-2032 (USD MILLION)
  • TABLE 187. G7 BRONCHIECTASIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 188. G7 BRONCHIECTASIS DRUGS MARKET SIZE, BY INJECTION, 2018-2032 (USD MILLION)
  • TABLE 189. G7 BRONCHIECTASIS DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD MILLION)
  • TABLE 190. G7 BRONCHIECTASIS DRUGS MARKET SIZE, BY BRONCHIECTASIS TYPE, 2018-2032 (USD MILLION)
  • TABLE 191. G7 BRONCHIECTASIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 192. NATO BRONCHIECTASIS DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 193. NATO BRONCHIECTASIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 194. NATO BRONCHIECTASIS DRUGS MARKET SIZE, BY ANTI-INFLAMMATORY AGENTS, 2018-2032 (USD MILLION)
  • TABLE 195. NATO BRONCHIECTASIS DRUGS MARKET SIZE, BY BRONCHODILATORS, 2018-2032 (USD MILLION)
  • TABLE 196. NATO BRONCHIECTASIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 197. NATO BRONCHIECTASIS DRUGS MARKET SIZE, BY INJECTION, 2018-2032 (USD MILLION)
  • TABLE 198. NATO BRONCHIECTASIS DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD MILLION)
  • TABLE 199. NATO BRONCHIECTASIS DRUGS MARKET SIZE, BY BRONCHIECTASIS TYPE, 2018-2032 (USD MILLION)
  • TABLE 200. NATO BRONCHIECTASIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 201. GLOBAL BRONCHIECTASIS DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 202. UNITED STATES BRONCHIECTASIS DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 203. UNITED STATES BRONCHIECTASIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 204. UNITED STATES BRONCHIECTASIS DRUGS MARKET SIZE, BY ANTI-INFLAMMATORY AGENTS, 2018-2032 (USD MILLION)
  • TABLE 205. UNITED STATES BRONCHIECTASIS DRUGS MARKET SIZE, BY BRONCHODILATORS, 2018-2032 (USD MILLION)
  • TABLE 206. UNITED STATES BRONCHIECTASIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 207. UNITED STATES BRONCHIECTASIS DRUGS MARKET SIZE, BY INJECTION, 2018-2032 (USD MILLION)
  • TABLE 208. UNITED STATES BRONCHIECTASIS DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD MILLION)
  • TABLE 209. UNITED STATES BRONCHIECTASIS DRUGS MARKET SIZE, BY BRONCHIECTASIS TYPE, 2018-2032 (USD MILLION)
  • TABLE 210. UNITED STATES BRONCHIECTASIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 211. CHINA BRONCHIECTASIS DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 212. CHINA BRONCHIECTASIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 213. CHINA BRONCHIECTASIS DRUGS MARKET SIZE, BY ANTI-INFLAMMATORY AGENTS, 2018-2032 (USD MILLION)
  • TABLE 214. CHINA BRONCHIECTASIS DRUGS MARKET SIZE, BY BRONCHODILATORS, 2018-2032 (USD MILLION)
  • TABLE 215. CHINA BRONCHIECTASIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 216. CHINA BRONCHIECTASIS DRUGS MARKET SIZE, BY INJECTION, 2018-2032 (USD MILLION)
  • TABLE 217. CHINA BRONCHIECTASIS DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD MILLION)
  • TABLE 218. CHINA BRONCHIECTASIS DRUGS MARKET SIZE, BY BRONCHIECTASIS TYPE, 2018-2032 (USD MILLION)
  • TABLE 219. CHINA BRONCHIECTASIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)